Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC.

J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749. Epub 2012 Aug 6.

2.
3.

Immunogenicity of human neuroblastoma.

Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V.

Ann N Y Acad Sci. 2004 Dec;1028:69-80. Review.

PMID:
15650233
4.

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM.

Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. eCollection 2015. Review.

5.

Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Perez Horta Z, Goldberg JL, Sondel PM.

Immunotherapy. 2016 Sep;8(9):1097-117. doi: 10.2217/imt-2016-0021. Review. Erratum in: Immunotherapy. 2016 Nov;8(11):1349.

6.

GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.

Gholamin S, Mirzaei H, Razavi SM, Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S, Avan A.

J Cell Physiol. 2018 Feb;233(2):866-879. doi: 10.1002/jcp.25793. Epub 2017 May 23. Review.

PMID:
28145567
7.

Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

Mora J.

Expert Rev Clin Pharmacol. 2016;9(5):647-53. doi: 10.1586/17512433.2016.1160775. Epub 2016 Mar 21. Review.

PMID:
26934530
8.

Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control.

Tu MM, Mahmoud AB, Makrigiannis AP.

Front Immunol. 2016 May 2;7:166. doi: 10.3389/fimmu.2016.00166. eCollection 2016. Review.

9.

Activating killer cell Ig-like receptors in health and disease.

Ivarsson MA, Michaƫlsson J, Fauriat C.

Front Immunol. 2014 Apr 22;5:184. doi: 10.3389/fimmu.2014.00184. eCollection 2014. Review.

10.

Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.

Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, Moretta A, Castriconi R.

Front Immunol. 2014 Feb 12;5:56. doi: 10.3389/fimmu.2014.00056. eCollection 2014. Review.

11.

Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Berois N, Osinaga E.

Front Oncol. 2014 May 23;4:114. doi: 10.3389/fonc.2014.00114. eCollection 2014. Review.

Supplemental Content

Support Center